TY - JOUR
T1 - Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity
AU - Sakai, Toshiyasu
AU - Terakura, Seitaro
AU - Miyao, Kotaro
AU - Okuno, Shingo
AU - Adachi, Yoshitaka
AU - Umemura, Koji
AU - Julamanee, Jakrawadee
AU - Watanabe, Keisuke
AU - Hamana, Hiroshi
AU - Kishi, Hiroyuki
AU - Leitner, Judith
AU - Steinberger, Peter
AU - Nishida, Tetsuya
AU - Murata, Makoto
AU - Kiyoi, Hitoshi
N1 - Publisher Copyright:
© 2020
PY - 2020/9/25
Y1 - 2020/9/25
N2 - An artificial T cell adaptor molecule (ATAM) was generated to improve persistence of T cell receptor (TCR) gene-transduced T (TCR-T) cells compared to such persistence in a preceding study. ATAMs are gene-modified CD3ζ with the intracellular domain of 4-1BB inserted in the middle of CD3ζ. NY-ESO-1 TCR-T cells transduced with an ATAM with two separated virus vectors demonstrated superior proliferation upon antigen stimulation. To further develop clinically applicable ATAM-transduced TCR-T cells, we attempted to make a single virus vector to transduce the TCR and ATAM simultaneously. Because we failed to observe improved proliferation capacity upon stimulation after one virus vector (1vv) transduction, we compared TCR-T cells transduced with 1vv and two virus vector (2vv) methods to elucidate the reason. In Jurkat reporter cells, an ATAM transduced by the 2vv method demonstrated a higher intensity than by the 1vv method, and the ATAM intensity was associated with increased nuclear factor κB (NF-κB) signals upon stimulation. In ATAM-transduced primary T cells, a transduced ATAM by the 2vv method showed higher intensity and better proliferation. ATAM-transduced TCR-T cells demonstrated improved proliferation only when the ATAM was transduced at a higher intensity. To create a simpler transduction method, we need to develop a strategy to make a higher ATAM expression to prove the efficacy of ATAM transduction in TCR-T therapy.
AB - An artificial T cell adaptor molecule (ATAM) was generated to improve persistence of T cell receptor (TCR) gene-transduced T (TCR-T) cells compared to such persistence in a preceding study. ATAMs are gene-modified CD3ζ with the intracellular domain of 4-1BB inserted in the middle of CD3ζ. NY-ESO-1 TCR-T cells transduced with an ATAM with two separated virus vectors demonstrated superior proliferation upon antigen stimulation. To further develop clinically applicable ATAM-transduced TCR-T cells, we attempted to make a single virus vector to transduce the TCR and ATAM simultaneously. Because we failed to observe improved proliferation capacity upon stimulation after one virus vector (1vv) transduction, we compared TCR-T cells transduced with 1vv and two virus vector (2vv) methods to elucidate the reason. In Jurkat reporter cells, an ATAM transduced by the 2vv method demonstrated a higher intensity than by the 1vv method, and the ATAM intensity was associated with increased nuclear factor κB (NF-κB) signals upon stimulation. In ATAM-transduced primary T cells, a transduced ATAM by the 2vv method showed higher intensity and better proliferation. ATAM-transduced TCR-T cells demonstrated improved proliferation only when the ATAM was transduced at a higher intensity. To create a simpler transduction method, we need to develop a strategy to make a higher ATAM expression to prove the efficacy of ATAM transduction in TCR-T therapy.
KW - CD3ζ gene modification
KW - T cell receptor gene insertion
KW - adaptor molecule gene-insertion intensity
KW - artificial adaptor molecule
KW - gene-modified T cell therapy
UR - http://www.scopus.com/inward/record.url?scp=85091105011&partnerID=8YFLogxK
U2 - 10.1016/j.omto.2020.08.014
DO - 10.1016/j.omto.2020.08.014
M3 - 学術論文
AN - SCOPUS:85091105011
SN - 2372-7705
VL - 18
SP - 613
EP - 622
JO - Molecular Therapy - Oncolytics
JF - Molecular Therapy - Oncolytics
ER -